268 related articles for article (PubMed ID: 28685948)
1. Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction.
Yamakawa Y; Tazawa H; Hasei J; Osaki S; Omori T; Sugiu K; Komatsubara T; Uotani K; Fujiwara T; Yoshida A; Kunisada T; Urata Y; Kagawa S; Ozaki T; Fujiwara T
Cancer Sci; 2017 Sep; 108(9):1870-1880. PubMed ID: 28685948
[TBL] [Abstract][Full Text] [Related]
2. Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells.
Hasei J; Sasaki T; Tazawa H; Osaki S; Yamakawa Y; Kunisada T; Yoshida A; Hashimoto Y; Onishi T; Uno F; Kagawa S; Urata Y; Ozaki T; Fujiwara T
Mol Cancer Ther; 2013 Mar; 12(3):314-25. PubMed ID: 23315976
[TBL] [Abstract][Full Text] [Related]
3. Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma.
Lamoureux F; Baud'huin M; Ory B; Guiho R; Zoubeidi A; Gleave M; Heymann D; Rédini F
Oncotarget; 2014 Sep; 5(17):7805-19. PubMed ID: 25138053
[TBL] [Abstract][Full Text] [Related]
4. Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model.
Labrinidis A; Hay S; Liapis V; Ponomarev V; Findlay DM; Evdokiou A
Clin Cancer Res; 2009 May; 15(10):3451-61. PubMed ID: 19401351
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic virotherapy reverses chemoresistance in osteosarcoma by suppressing MDR1 expression.
Sugiu K; Tazawa H; Hasei J; Yamakawa Y; Omori T; Komatsubara T; Mochizuki Y; Kondo H; Osaki S; Fujiwara T; Yoshida A; Kunisada T; Ueda K; Urata Y; Kagawa S; Ozaki T; Fujiwara T
Cancer Chemother Pharmacol; 2021 Sep; 88(3):513-524. PubMed ID: 34114067
[TBL] [Abstract][Full Text] [Related]
6. Blocking HSP90 Addiction Inhibits Tumor Cell Proliferation, Metastasis Development, and Synergistically Acts with Zoledronic Acid to Delay Osteosarcoma Progression.
Ory B; Baud'huin M; Verrecchia F; Royer BB; Quillard T; Amiaud J; Battaglia S; Heymann D; Redini F; Lamoureux F
Clin Cancer Res; 2016 May; 22(10):2520-33. PubMed ID: 26712686
[TBL] [Abstract][Full Text] [Related]
7. Anticancer effects of zoledronic acid against human osteosarcoma cells.
Kubista B; Trieb K; Sevelda F; Toma C; Arrich F; Heffeter P; Elbling L; Sutterlüty H; Scotlandi K; Kotz R; Micksche M; Berger W
J Orthop Res; 2006 Jun; 24(6):1145-52. PubMed ID: 16602111
[TBL] [Abstract][Full Text] [Related]
8. Combined Use of Zoledronic Acid Augments Ursolic Acid-Induced Apoptosis in Human Osteosarcoma Cells through Enhanced Oxidative Stress and Autophagy.
Wu CC; Huang YF; Hsieh CP; Chueh PJ; Chen YL
Molecules; 2016 Nov; 21(12):. PubMed ID: 27916903
[TBL] [Abstract][Full Text] [Related]
9. Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis.
Evdokiou A; Labrinidis A; Bouralexis S; Hay S; Findlay DM
Bone; 2003 Aug; 33(2):216-28. PubMed ID: 14499355
[TBL] [Abstract][Full Text] [Related]
10. Zoledronic acid is an effective radiosensitizer in the treatment of osteosarcoma.
Kim EH; Kim MS; Lee KH; Koh JS; Jung WG; Kong CB
Oncotarget; 2016 Oct; 7(43):70869-70880. PubMed ID: 27765919
[TBL] [Abstract][Full Text] [Related]
11. Zoledronic acid inhibits osteosarcoma growth in an orthotopic model.
Dass CR; Choong PF
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3263-70. PubMed ID: 18089720
[TBL] [Abstract][Full Text] [Related]
12. Ablation of MCL1 expression by virally induced microRNA-29 reverses chemoresistance in human osteosarcomas.
Osaki S; Tazawa H; Hasei J; Yamakawa Y; Omori T; Sugiu K; Komatsubara T; Fujiwara T; Sasaki T; Kunisada T; Yoshida A; Urata Y; Kagawa S; Ozaki T; Fujiwara T
Sci Rep; 2016 Jun; 6():28953. PubMed ID: 27356624
[TBL] [Abstract][Full Text] [Related]
13. Effect of zoledronic acid and amputation on bone invasion and lung metastasis of canine osteosarcoma in nude mice.
Wolfe TD; Pillai SP; Hildreth BE; Lanigan LG; Martin CK; Werbeck JL; Rosol TJ
Clin Exp Metastasis; 2011 Apr; 28(4):377-89. PubMed ID: 21374084
[TBL] [Abstract][Full Text] [Related]
14. Telomerase-specific oncolytic immunotherapy for promoting efficacy of PD-1 blockade in osteosarcoma.
Mochizuki Y; Tazawa H; Demiya K; Kure M; Kondo H; Komatsubara T; Sugiu K; Hasei J; Yoshida A; Kunisada T; Urata Y; Kagawa S; Ozaki T; Fujiwara T
Cancer Immunol Immunother; 2021 May; 70(5):1405-1417. PubMed ID: 33151368
[TBL] [Abstract][Full Text] [Related]
15. Zoledronic Acid Enhanced the Antitumor Effect of Cisplatin on Orthotopic Osteosarcoma by ROS-PI3K/AKT Signaling and Attenuated Osteolysis.
Liu L; Geng H; Mei C; Chen L
Oxid Med Cell Longev; 2021; 2021():6661534. PubMed ID: 33859780
[TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat model.
Labrinidis A; Hay S; Liapis V; Findlay DM; Evdokiou A
Int J Cancer; 2010 Jul; 127(2):345-54. PubMed ID: 19924813
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL.
Ohba T; Cole HA; Cates JM; Slosky DA; Haro H; Ando T; Schwartz HS; Schoenecker JG
J Bone Miner Res; 2014 Jun; 29(6):1431-45. PubMed ID: 24443409
[TBL] [Abstract][Full Text] [Related]
18. Efficient virotherapy for osteosarcoma by telomerase-specific oncolytic adenovirus.
Li G; Kawashima H; Ogose A; Ariizumi T; Xu Y; Hotta T; Urata Y; Fujiwara T; Endo N
J Cancer Res Clin Oncol; 2011 Jun; 137(6):1037-51. PubMed ID: 21193997
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic virotherapy promotes radiosensitivity in soft tissue sarcoma by suppressing anti-apoptotic MCL1 expression.
Omori T; Tazawa H; Yamakawa Y; Osaki S; Hasei J; Sugiu K; Komatsubara T; Fujiwara T; Yoshida A; Kunisada T; Urata Y; Kagawa S; Ozaki T; Fujiwara T
PLoS One; 2021; 16(4):e0250643. PubMed ID: 33886686
[TBL] [Abstract][Full Text] [Related]
20. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents.
Koto K; Murata H; Kimura S; Horie N; Matsui T; Nishigaki Y; Ryu K; Sakabe T; Itoi M; Ashihara E; Maekawa T; Fushiki S; Kubo T
Oncol Rep; 2010 Jul; 24(1):233-9. PubMed ID: 20514467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
